vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Peraso Inc. (PRSO). Click either name above to swap in a different company.
Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.9M, roughly 1.4× Peraso Inc.). Peraso Inc. runs the higher net margin — -43.3% vs -238.2%, a 194.9% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.
CTXR vs PRSO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.9M |
| Net Profit | $-9.4M | $-1.2M |
| Gross Margin | 80.0% | 52.2% |
| Operating Margin | -228.7% | -44.6% |
| Net Margin | -238.2% | -43.3% |
| Revenue YoY | — | -22.0% |
| Net Profit YoY | 8.6% | 20.3% |
| EPS (diluted) | $-0.38 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $2.9M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | — | $3.7M | ||
| Q3 24 | — | $3.8M | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | $-9.4M | $-1.2M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-471.0K | ||
| Q4 24 | — | $-1.6M | ||
| Q3 24 | — | $-2.7M | ||
| Q2 24 | — | $-4.4M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | 80.0% | 52.2% | ||
| Q3 25 | — | 56.2% | ||
| Q2 25 | — | 48.3% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 47.0% | ||
| Q2 24 | — | 55.5% | ||
| Q1 24 | — | 46.4% |
| Q4 25 | -228.7% | -44.6% | ||
| Q3 25 | — | -36.8% | ||
| Q2 25 | — | -80.0% | ||
| Q1 25 | — | -13.3% | ||
| Q4 24 | — | -44.3% | ||
| Q3 24 | — | -70.3% | ||
| Q2 24 | — | -105.6% | ||
| Q1 24 | — | -128.9% |
| Q4 25 | -238.2% | -43.3% | ||
| Q3 25 | — | -37.4% | ||
| Q2 25 | — | -82.4% | ||
| Q1 25 | — | -12.2% | ||
| Q4 24 | — | -42.4% | ||
| Q3 24 | — | -70.6% | ||
| Q2 24 | — | -104.4% | ||
| Q1 24 | — | -72.1% |
| Q4 25 | $-0.38 | $-0.09 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.31 | ||
| Q1 25 | — | $-0.10 | ||
| Q4 24 | — | $0.36 | ||
| Q3 24 | — | $-0.98 | ||
| Q2 24 | — | $-1.88 | ||
| Q1 24 | — | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $4.6M |
| Total Assets | $140.4M | $6.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $2.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $2.4M |
| Q4 25 | $80.0M | $4.6M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $6.7M |
| Q4 25 | $140.4M | $6.1M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | — | $5.5M | ||
| Q1 25 | — | $6.7M | ||
| Q4 24 | — | $7.2M | ||
| Q3 24 | — | $7.2M | ||
| Q2 24 | — | $9.8M | ||
| Q1 24 | — | $11.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-1.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-1.1M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-966.0K | ||
| Q4 24 | — | $-687.0K | ||
| Q3 24 | — | $-683.0K | ||
| Q2 24 | — | $-659.0K | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -48.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTXR
Segment breakdown not available.
PRSO
| Products | $2.8M | 96% |
| Other | $105.0K | 4% |
